Jang et al. [35] mentioned that GERM1-expressing fibroblasts were closely associated with lower invasiveness and better prognosis in CRC, suggesting that stromal GREM1 may represent a novel target for the treatment of CRCs and a potential biomarker. Here, GREM1 is linked to colorectal carcinoma.